83-5966-05　CD22, Epratuzumab Biosimilar 1mg　591839

特徴

• Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab.
• Epratuzumab is a humanized monoclonal antibody derived from the murine IgG2a monoclonal antibody, LL2 (EPB-2).
• This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
• Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
• It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22.
• After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Epratuzumab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.